Regarding Techcyte and Biobase Partnership on LinkedIn
recent articles
From LinkedIn regarding Techcyte and Biobase partnership Sam Seymour, CPO and Co-Founder at Biobase: I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology's adoption...
OREM, UT, UNITED STATES, May 4, 2026 /EINPresswire.com/ -- Techcyte is pleased to announce that a validation study conducted by the Contra Costa County Public Health Laboratory (CCPHL) evaluating its AI-assisted ova and parasite (O&P)...
From the Proscia blog: Going digital is a huge feat, and something well worth celebrating. But the labs seeing the biggest returns chose a platform that keeps compounding value long after go-live, scaling across departments and teams without...
Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly...
From the Proscia blog: We’ve long said that the next major therapeutic breakthrough may lie in pathology data that already exists. At this year’s AACR Annual Meeting, it became clear the biopharma community is arriving at the same...
Regarding the Roche acquisition of PathAI, from Elizabeth Bourn on LinkedIn: This morning, Roche announced that it had entered into a definitive merger agreement to acquire PathAI for $750M upfront, with up to $300M in additional milestone...
